ProCE Banner Activity

Alectinib: A New Standard of Care for Newly Diagnosed Advanced ALK-Positive NSCLC

Clinical Thought
New data from ASCO 2017 has established alectinib as a new standard of care for newly diagnosed ALK-positive NSCLC. Alice Shaw, MD, PhD, discusses the latest clinical data from the ALEX trial supporting this landmark change in advanced NSCLC management.

Released: July 07, 2017

Expiration: July 06, 2018

Share

Faculty

Alice Shaw

Alice Shaw, MD, PhD

Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Celgene

Genentech Roche Virology

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Alice Shaw, MD, PhD

Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Alice Shaw, MD, PhD, has disclosed that she has received consulting fees from ARIAD, Blueprint Medicines, Daiichi Sankyo, EMD Serono, Genentech, Ignyta, Loxo Oncology, Novartis, Pfizer, Roche, and Taiho Oncology.